[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337614-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337614-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","predictive-value-and-therapeutic-significance-of-somatic-brca-mutation-in-solid-tumors","Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors","","Ten percent of patients with breast cancer, and likely more in ovarian cancer, carry inherited germline BRCA1/BRCA2 DNA mutations. In the remaining patients, tumor development is driven by acquired somatic genetic and epigenetic alterations. Targeted agents such as PARP inhibitors (PARPi) have shown clinical activity, with BRCA deleterious variants and homologous recombination deficiency often predicting response. Yet the clinical relevance of somatic BRCA mutations is less established; recent cases and randomized studies support PARPi effectiveness. This review summarizes predictive value and therapeutic implications of somatic BRCA mutations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/predictive-value-and-therapeutic-significance-of-somatic-brca-mutation-in-solid-tumors/337614/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/predictive-value-and-therapeutic-significance-of-somatic-brca-mutation-in-solid-tumors/337614.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What proportion of breast and ovarian cancer patients have germline BRCA mutations?","Question",{"text":63,"@type":64},"About 10% of breast cancer patients carry inherited germline BRCA1/2 mutations, and the proportion is likely somewhat higher in ovarian cancer patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do somatic BRCA mutations differ from germline mutations in detection and origin?",{"text":68,"@type":64},"Germline BRCA is usually detected in blood, while somatic BRCA mutations can be identified from genomic profiling of tumor tissue or testing circulating tumor DNA.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is the predictive role of somatic BRCA mutations less clear than germline mutations?",{"text":72,"@type":64},"The review notes that although targeted PARPi therapies are effective in cancers linked to germline BRCA mutations, the relevance of somatic BRCA mutations has been less established and remains a debated topic.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337614,1790156000,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","biomedicines  \nReview  \nPredictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors  \nGyongyver Szentmartoni *, Dorottya Mühl, Renata Csanda, Attila Marcell Szasz , Zoltan Herold  and Magdolna Dank   \nCitation: Szentmartoni, G.; Mühl, D.; Csanda, R.; Szasz, A.M.; Herold, Z.; Dank, M. Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors. Biomedicines 2024, 12, 593 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)biomedicines12030593  \nAcademic Editor: Raghu Sinha  \nReceived: 29 December 2023  \nRevised: 28 February 2024  \nAccepted: 5 March 2024  \nPublished: 6 March 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary  \n* Correspondence: [szentmartoni.gyongyver@med.semmelweis-univ.hu](szentmartoni.gyongyver@med.semmelweis-univ.hu); Tel.: +36-1-459-1500  \nAbstract: Ten percent of patients with breast cancer, and probably somewhat more in patients with ovarian cancer, have inherited germline DNA mutations in the breast and ovarian cancer genes BRCA1 and BRCA2 . In the remaining cases, the disease is caused by acquired somatic genetic and epigenetic alterations. Targeted therapeutic agents, such as poly ADP-ribose polymerases (PARP) inhibitors (PARPi), have emerged in treating cancers associated with germline BRCA mutations since 2014 . The first PARPi was FDA-approved initially for ovarian cancer patients with germline BRCA mutations. Deleterious variants in the BRCA1/BRCA2 genes and homologous recombination deficiency status have been strong predictors of response to PARPi in a few solid tumors since then. However, the relevance of somatic BRCA mutations is less clear. Somatic BRCA-mutated tumors might also respond to this new class of therapeutics. Although the related literature is often controversial, recently published case reports and/or randomized studies demonstrated the effectiveness of PARPi in treating patients with somatic BRCA mutations. The aim of this review is to summarize the predictive role of somatic BRCA mutations and to provide further assistance for clinicians with the identification of patients who could potentially benefit from PARPi.  \nKeywords: somatic BRCA1/2; PARP inhibition; breast neoplasms; ovarian neoplasms; pancreatic neoplasms; prostatic neoplasms  \n1. Introduction  \nThe discovery of the BReast CAncer (BRCA) genes in the early 1990s, namely BRCA1 and BRCA2, may be considered as one of the most significant achievements in medicine lately. It was found that both genes play a crucial role in the development of hereditary breast cancer (BC) . Moreover, it soon became clear that these genes are involved in the pathogenesis of familial ovarian cancer. BRCA1 and/or BRCA2 gene mutations have since been shown to play a role in many more tumor types [1–3] . BRCA1 was discovered in 1994, and it is located on chromosome 17q21 containing 22 exons. BRCA2 was discovered a year later, in 1995, contains 27 exons, and it is located on chromosome 13q12 [2] . Of the two transcriptomes, the BRCA2 protein is the larger, which is mostly involved in homologous recombination (HR) . The BRCA1 protein has more active functions, which are carried out through various functional domains of the molecule that can interact with a range of other proteins. Its involvement in DNA repair, checkpoint control of the cell cycle, protein ubiquitination, and chromatin remodeling were previously described [2,4] .  \nThe BRCA1 and BRCA2 genes are indirect tumor suppressor stability genes [3] . Both germline (gBRCA) and somatic (s","cbCaidFWysWYdmM9","https://ap.wps.com/l/cbCaidFWysWYdmM9","pdf",1107244,17,"English","# Introduction\n# BRCA1 and BRCA2: biology and genomic context\n## Germline versus somatic mutations\n## Risk, prevalence, and detection\n# Predictive value and PARP inhibitor response","[{\"question\":\"What proportion of breast and ovarian cancer patients have germline BRCA mutations?\",\"answer\":\"About 10% of breast cancer patients carry inherited germline BRCA1/2 mutations, and the proportion is likely somewhat higher in ovarian cancer patients.\"},{\"question\":\"How do somatic BRCA mutations differ from germline mutations in detection and origin?\",\"answer\":\"Germline BRCA is usually detected in blood, while somatic BRCA mutations can be identified from genomic profiling of tumor tissue or testing circulating tumor DNA.\"},{\"question\":\"Why is the predictive role of somatic BRCA mutations less clear than germline mutations?\",\"answer\":\"The review notes that although targeted PARPi therapies are effective in cancers linked to germline BRCA mutations, the relevance of somatic BRCA mutations has been less established and remains a debated topic.\"}]","Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors | PDF",1790019802,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8dfb141df80b192b16d5981710da903c.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc743b37b1a36e1b362d3bee5f2cbe15.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e905ec57ff324520890a2368dbba1e1.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7514b75412a1a4d3fd537509a3d0ecc.webp",980,1385]